Shrimp the Next Food Source to Receive RNA-Based Vaccines?

Posted by on September 17, 2023 3:04 am

Shrimp is the latest part of our food supply slated for exposure to RNA-based vaccines.

ViAqua Therapeutics, an Israeli-based biotechnology company, is developing an orally-delivered “platform for targeted administration of RNA-based solutions” for shrimp.

“The Company’s first product will be incorporated into a commercially produced shrimp feed for maintaining the health status of shrimp and improving their ability to cope with viral disease challenges,” the company’s website reads.

“The company’s first product is feed supplement for the improved resistance to viral diseases in shrimp, with the initial application against the widespread White Spot Shrimp Virus (WSSV),” ViAqua states.

RNAi is a non-GMO, hormone-free supplement that is safe for shrimp and humans. It is a non-antibiotic, feed-grade material. ViAqua utilizes RNAi as a means to maintain the health status of shrimp and improve their ability to cope with viral disease challenges,” ViAqua states.

“Oral delivery is the holy grail of aquaculture health development due to both the impossibility of vaccinating individual shrimp and its ability to substantially bring down the operational costs of disease management while improving outcomes,” said ViAqua CEO Shai Ufaz.

“We are excited to bring this technology to market to address the need for affordable disease solutions in aquaculture.”

According to reports, ViAqua Therapeutics received $8.25 million in funding from venture capitalists to develop its oral-based shrimp vaccine.

From PR Newswire:

ViAqua Therapeutics, a biotechnology company and developer of an orally administered RNA-particle platform to promote and improve animal health in aquaculture, announced it has completed a US$8.25M round led by S2G Ventures with participation from Rabo Ventures, The Trendlines Group Ltd., Agriline Limited, Nutreco, I-Lab Angels and Circle Investments LLC.

Aquaculture is essential for improving food security, providing a healthy and sustainable food source, and protecting wild fish stocks in the face of growing demand for marine protein. But disease management is currently the biggest issue facing the aquaculture industry, resulting in more than $8.5 billion in economic impact for the shrimp industry alone, according to an analysis from Kontali.

To address this problem, ViAqua has developed a biotechnology-based oral delivery platform for the targeted administration of RNA-based solutions to improve disease resistance in aquaculture.

“Funding will enable ViAqua to bring its first product to market, invest in R&D for future products, and prove the platform’s ability to deliver RNA-based solutions at scale,” the September press release read.

“ViAqua’s platform technology will enable the company to move beyond WSSV to address numerous other diseases in aquaculture while similar technologies are still years away from reaching the market,” said Kate Danaher, managing director of S2G Ventures’ Ocean and Seafood fund.

ViAqua plans to bring its product to market in 2024.

Cont. from PR Newswire:

ViAqua produces its capsule products using commercial, industrial processes and is scaling production to take its first product to market. With plans to begin production in India at the beginning of 2024, the company has established a commercial partnership through a joint development and marketing agreement with Skretting, a Nutreco company, to bring the product to the market. While ViAqua is currently focused on shrimp production, the delivery technology has numerous applications in aquaculture and beyond, which the company is excited to explore.

“We are truly excited by the potential of ViAqua’s technology because of the value it unlocks for the planet and the farmers. Diseases cause mortality rates of up to 50%, which result in 25-30% of shrimp farms failing annually. This is tremendously unproductive and hurts a lot of livelihoods,” explained Shishir Sinha, investment director at Rabo Ventures. “Our bank’s aquaculture specialists Gorjan Nikolik and Novel Sharma were impressed by the game-changing impact potential of having a solution for an issue that has plagued the sector for decades and can make a meaningful difference in the lives of the smallholder farmers, who represent 80% of supply.”

Shrimp isn’t the first food item to receive RNA-based vaccines.

The Expose explained:

The media has been pretty quiet about the up-and-coming genetic manipulation of shrimp. This seems to be par for the course. Few are aware that, since 2018, pork producers have been using customizable mRNA-based “vaccines” on their herds — as it largely slipped by under the radar.11

It wasn’t until attorney Tom Renz began promoting new legislation in Missouri (House Bill 1169,12 which he helped write) that would require labeling of mRNA products that it began to receive attention.13 In an April 1, 2023, tweet, Renz stated:14

“BREAKING NEWS: the lobbyists for the cattleman and pork associations in several states have CONFIRMED they WILL be using mRNA vaccines in pigs and cows THIS MONTH. WE MUST SUPPORT MISSOURI HB1169. It is LITERALLY the ONLY chance we have to prevent this … NO ONE knows the impacts of doing this but we are all potentially facing the risk of being a #DiedSuddenly if we don’t stop this.”

Even though the bill asks only for transparency — not a ban of the mRNA-based shots — industry pushback has been enormous. They don’t want you to know that they’re using mRNA and similar products, because then they’d have to admit that the resulting foods may have gene-altering effects. And it’s not just pork, either.

Read more about mRNA vaccines for pigs and cattle at WLTReport.

BREAKING: mRNA Vaxx Going Into Pigs and Cow Milk THIS MONTH!